The 14 Billion Dose COVID-19 Manufacturing Challenge
mRNA Vaccines Leading The Way
Manufacturing COVID-19 vaccines at unprecedented speed and scale is 2021’s biggest challenge – and mRNA platforms are emerging as the leaders, living up to their promise as the ideal technology for pandemic preparedness.
You may also be interested in...
Pfizer moved aggressively and early as COVID-19 became a global health threat, and now the company, with its partner BioNTech, is the first to secure an emergency use authorization for a COVID vaccine from the US FDA.
The UK biotech aims to raise $100m, but will need to tackle safety concerns to secure a long-term future.
Sanofi has paid out $160m to add to its in-house expertise in mRNA and novel cell therapy technologies.